References
- Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12: 310–350
- Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 3: 161–172
- Pfaller MA, Rinaldi MG. Antifungal susceptibility testing. Current state of technology, limitations, and standardization. Infect Dis Clin North Am 1993; 2: 435–444
- Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole pre-exposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002; 46: 3208–3214
- Denning DW, Anderson MJ, Turner G, Latge JP, Bennett JW. Sequencing the Aspergillus fumigatus genome. Lancet Infect Dis 2002; 2: 251–253
- Brakhage AA, Langfelder K. Menacing mold: the molecular biology of Aspergillus fumigatus. Annu Rev Microbiol 2002; 56: 433–455
- Tsai HF, Chang YC, Washburn RG, Wheeler MH, Kwon-Chung KJ. The developmentally regulated alb1 gene of Aspergillus fumigatus: its role in modulation of conidial morphology and virulence. J Bacteriol 1998; 180: 3031–3038
- Panepinto JC, Oliver BG, Fortwendel JR, et al. Deletion of the Aspergillus fumigatus gene encoding the Ras-related protein RhbA reduces virulence in a model of invasive pulmonary aspergillosis. Infect Immun 2003; 71: 2819–2826
- Bhabhra R, Miley MD, Mylonakis E, et al. Disruption of the Aspergillus fumigatus gene encoding nucleolar protein CgrA impairs thermotolerant growth and reduces virulence. Infect Immun 2004; 72: 4731–4740
- Apidianakis Y, Rahme LG, Heitman J, et al. Challenge of Drosophila melanogaster with Cryptococcus neoformans and role of the innate immune response. Eukaryot Cell 2004; 3: 413–419
- Alarco A, Marcil A, Chen J, et al. Immune-deficient Drosophila melanogaster: a model for the innate immune response to human fungal pathogens. J Immunol 2004; 172: 5622–5628
- Steenbergen JN, Shuman HA, Casadevall A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci USA 2001; 98: 15245–15250
- Garsin DA, Sifri CD, Mylonakis E, et al. A simple model host for identifying Gram-positive virulence factors. Proc Natl Acad Sci USA 2001; 98: 10892–10897
- Mylonakis E, Ausubel FM, Perfect JR, Heitman J, Calderwood SB. Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci USA 2002; 99: 15675–15680
- Sifri CD, Mylonakis E, Singh KV, et al. Virulence effect of Enterococcus faecalis protease genes and the quorum-sensing locus fsr in Caenorhabditis elegans and mice. Infect Immun 2002; 70: 5647–5650
- Hoffmann JA, Reichhart JM. Drosophila innate immunity: an evolutionary perspective. Nat Immunol 2002; 3: 121–126
- Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86: 973–983
- Lemaitre B, Reichhart JM, Hoffmann JA. Drosophila host defense: differential induction of antimicrobial peptide genes after infection by various classes of microorganisms. Proc Natl Acad Sci USA 1997; 94: 14614–14619
- Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science 1999; 284: 1313–1318
- Morisato D, Anderson KV. Signaling pathways that establish the dorsal-ventral pattern of the Drosophila embryo. Annu Rev Genet 1995; 29: 371–399
- Lionakis, MS, Halder, G, Lewis, RE, , et al. A non-vertebrate in vivo model to study invasive aspergillosis (IA) and its treatment with oral antifungals: early experience with Drosophila. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2003. Abstract #M–477.
- Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41: 696–698
- Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
- Lionakis, MS, Halder, G, Lewis, RE, Wiederhold, NP, Kontoyiannis, DP. Efficacy of voriconazole in experimental aspergillosis in Drosophila. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 2004. Abstract M-1139.
- Mosquera J, Sharp A, Moore CB, Warn PA, Denning DW. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002; 50: 189–194
- Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001; 39: 91–95
- Barchiesi F, Di Francesco LF, Compagnucci P, et al. In vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of C. albicans. J Antimicrob Chemother 1998; 41: 59–65
- Lionakis, MS, Halder, G, Lewis, RE, , et al. Experimental aspergillosis in Drosophila: influence of mode of infection on Aspergillus virulence. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 2004. Abstract M-223.